# Patient-Trial Match Report

*Generated: 2026-01-05 18:30:22*

## Patient Profile

- **Age**: 48
- **Sex**: Female
- **Cancer Type**: breast cancer
- **Biomarkers**: HER2 positive, ER positive, PR negative

**Clinical Description**:
> 48-year-old premenopausal female with HER2-positive (IHC 3+, FISH amplified), ER+/PR- metastatic breast cancer. Originally diagnosed as Stage IIA in 2021, received neoadjuvant TCHP with pCR. Developed bone-only metastatic recurrence 2 years later. First-line trastuzumab/pertuzumab + docetaxel achieved PR, then progression at 10 months. Second-line T-DM1 ongoing x6 cycles with mixed response - new liver lesions noted. Interested in ADC combinations or novel HER2 agents. Baseline cardiac function LVEF 58%. No CNS disease. Mild neuropathy from prior taxanes.

- **Location Preference**: United States

## Search Summary

- **Search terms used**: 14
- **Total trials evaluated**: 100
- **Excluded by fast filter**: 44
- **LLM scored**: 56

## ðŸŸ¢ HIGH Likelihood (6 trials)

### [NCT05230810](https://clinicaltrials.gov/study/NCT05230810)

**This is a Multicenter, Single Arm, Open-label, run-in Phase Ib / Roll-over Phase II Study of Tucatinib in Combination With Alpelisib in Subjects With PIK3CA-mutant HER2-positive Locally Advanced Unresectable or Metastatic Breast Cancer.**

- **Sponsor**: Criterium, Inc.
- **Phase**: Phase 1/Phase 2
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Age: 48
- ECOG status: 1
- Cancer type: HER2-positive metastatic breast cancer
- Biomarker: PIK3CA H1047R identified
- Prior therapies: Received at least two FDA-approved HER2-targeted agents
- No brain metastases

**Assessment:**
> The patient's cancer type and progression match the trial's indication for HER2-positive metastatic breast cancer with a PIK3CA mutation. The patient fits the treatment line as they have received multiple prior therapies. Their ECOG performance status and age also align with the eligibility criteria.

---

### [NCT05325632](https://clinicaltrials.gov/study/NCT05325632)

**A Phase II Study of Human Epidermal Growth Factor Receptor 2 (HER-2) Directed Dendritic Cell (DC1) Vaccine Plus Weekly Paclitaxel, Trastuzumab and Pertuzumab in Patients With HER-2 Positive Breast Cancer**

- **Sponsor**: H. Lee Moffitt Cancer Center and Research Institute
- **Phase**: Phase 2
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- HER2-positive breast cancer matches trial condition
- ECOG status 1 meets trial criteria
- No CNS disease aligns with eligibility

**? Uncertainties:**
- Normal organ and marrow function unspecified
- Confirmation if patient is candidate for neoadjuvant chemotherapy with Paclitaxel, Trastuzumab, and Pertuzumab

**Assessment:**
> The patient's breast cancer is HER2-positive, aligning with the trial's indication. The patient falls within the appropriate ECOG performance status. However, there are uncertainties regarding normal organ function and whether the patient qualifies for the specified treatment regimen.

---

### [NCT05748834](https://clinicaltrials.gov/study/NCT05748834)

**Phase 2 Single Arm Trial With a Safety Lead-in of Tucatinib in Combination With Doxil for the Treatment of HER2+ Metastatic Breast Cancer**

- **Sponsor**: SCRI Development Innovations, LLC
- **Phase**: Phase 2
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Confirmed diagnosis of HER2+ metastatic breast cancer
- ECOG status 1
- Prior treatment with anti-HER2 therapies
- No evidence of brain metastases
- LVEF 58% (â‰¥50%)

**? Uncertainties:**
- Exact values of hematologic and hepatic function tests (ANC, platelets, hemoglobin, bilirubin, AST, ALT, eGFR)

**Assessment:**
> The patient's cancer type matches the trial's focus on HER2+ metastatic breast cancer. The patient has prior therapies and an ECOG status of 1, meeting the study's criteria for being previously treated. No brain metastases are present, and LVEF is acceptable. Minor uncertainties remain regarding specific organ function test values.

---

### [NCT04899908](https://clinicaltrials.gov/study/NCT04899908)

**A Double-blind, Phase II Randomized Study of Brain-directed Stereotactic Radiation With or Without AGuIX Gadolinium-based Nanoparticles in the Management of Brain Metastases at Higher Risk of Local Recurrence With Radiation Alone**

- **Sponsor**: Dana-Farber Cancer Institute
- **Phase**: Phase 2
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- HER2 positive breast cancer
- Age 48
- ECOG status 1
- No CNS disease
- Estimated survival based on extracranial disease of at least 3 months

**? Uncertainties:**
- Estimated glomerular filtration rate
- Ability to undergo a brain MRI
- Ability to receive gadolinium
- Willingness to use contraception prior to study entry

**Assessment:**
> The patient's cancer type matches the study's indications as she has HER2-positive breast cancer. She has a suitable ECOG status and no CNS disease. Although there are uncertainties regarding organ function and imaging, the key eligibility criteria are met.

---

### [NCT06695845](https://clinicaltrials.gov/study/NCT06695845)

**A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206)**

- **Sponsor**: Jazz Pharmaceuticals
- **Phase**: Phase 2
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Age: 48
- Sex: female
- Cancer type: breast cancer
- Biomarkers: HER2 positive (IHC 3+)
- ECOG status: 1
- No brain metastases
- Prior therapies: TCHP, trastuzumab, pertuzumab, docetaxel, T-DM1

**? Uncertainties:**
- Adequate organ functions
- Presence of at least 1 measurable lesion
- Tumor sample for submission for central testing
- Life expectancy of at least 3 months

**Assessment:**
> The patient's cancer type is breast cancer, which matches the trial's conditions studied. The patient has received prior HER2-targeted therapies, which aligns with the inclusion criteria for the breast cancer cohort of the trial. The ECOG status and other factors indicate potential eligibility, but some specifics (like organ function and measurable lesions) are uncertain.

---

### [NCT03740256](https://clinicaltrials.gov/study/NCT03740256)

**A First in Human Phase I Trial of Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR T Cells in Patients With Advanced HER2 Positive Solid Tumors**

- **Sponsor**: Baylor College of Medicine
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 75%

**âœ“ Supporting Factors:**
- Patient has HER2 positive breast cancer.
- Patient has progressed after first-line therapy.
- Patient's ECOG status is 1, acceptable for the trial.

**? Uncertainties:**
- Biomarker confirmation for HER2 positivity (IHC 3+ is positive but missing specific staining criteria confirmation).
- Radiographically measurable disease not confirmed with RECIST 1.1 details.
- Adequate organ function tests (e.g., hematologic, hepatic, renal) not provided.

**Assessment:**
> The patient's cancer type matches the trial's focus on HER2 positive breast cancer and they have progressed after standard first-line therapy. Although there are a few uncertainties regarding specific eligibility criteria and organ function, the main criteria align well with the trial requirements.

---

## ðŸŸ¡ MEDIUM Likelihood (1 trials)

### [NCT06055881](https://clinicaltrials.gov/study/NCT06055881)

**Primary Breast Oligoprogressive Sites Treated With Radiotherapy to Obviate the Need to Change Systemic Therapy (BOSS)**

- **Sponsor**: Mayo Clinic
- **Phase**: Not Applicable
- **Status**: Recruiting
- **Confidence**: 60%

**âœ“ Supporting Factors:**
- Age: 48
- Sex: female
- Cancer type: breast cancer
- ECOG status: 1
- Prior therapies: TCHP, trastuzumab, pertuzumab, docetaxel, T-DM1
- Brain metastases: none

**âœ— Potential Conflicts:**
- Prior therapies exceeded 6 months for second-line therapy but may not fulfill the requirement of oligoprogressive disease in 1-3 sites.
- Patient notes mixed response with new liver lesions suggesting potential complications with oligoprogression.

**? Uncertainties:**
- Number of extracranial sites of oligoprogressive disease is unknown, as it is not explicitly stated.
- History of radiation therapy is not mentioned.
- Confirmation of circulating tumor cells in bloodstream is not provided.

**Assessment:**
> The patient's cancer type (breast cancer) aligns with the trial's indication. However, the treatment line eligibility requires clarification on the status of oligoprogressive disease and the number of extracranial sites. There are also uncertainties regarding prior radiation therapy and circulating tumor cell confirmation. Thus, while there is a potential for eligibility, verification of these criteria is needed.

---

## Excluded (93 trials)

### Excluded by Fast Filter

| NCT ID | Reason |
|--------|--------|
| [NCT05557877](https://clinicaltrials.gov/study/NCT05557877) | Patient age 48 is above maximum age 45 |
| [NCT06139107](https://clinicaltrials.gov/study/NCT06139107) | Patient age 48 is below minimum age 60 |
| [NCT02693535](https://clinicaltrials.gov/study/NCT02693535) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT03011684](https://clinicaltrials.gov/study/NCT03011684) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT03675893](https://clinicaltrials.gov/study/NCT03675893) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT04250259](https://clinicaltrials.gov/study/NCT04250259) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT04771130](https://clinicaltrials.gov/study/NCT04771130) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT04844528](https://clinicaltrials.gov/study/NCT04844528) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT04883437](https://clinicaltrials.gov/study/NCT04883437) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05134012](https://clinicaltrials.gov/study/NCT05134012) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05405595](https://clinicaltrials.gov/study/NCT05405595) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05417594](https://clinicaltrials.gov/study/NCT05417594) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05463263](https://clinicaltrials.gov/study/NCT05463263) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05783609](https://clinicaltrials.gov/study/NCT05783609) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05853575](https://clinicaltrials.gov/study/NCT05853575) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05874193](https://clinicaltrials.gov/study/NCT05874193) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05888493](https://clinicaltrials.gov/study/NCT05888493) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05903092](https://clinicaltrials.gov/study/NCT05903092) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05916196](https://clinicaltrials.gov/study/NCT05916196) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05978518](https://clinicaltrials.gov/study/NCT05978518) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| ... | *and 24 more* |

### Excluded by Eligibility Assessment

| NCT ID | Sponsor | Reason |
|--------|---------|--------|
| [NCT03971409](https://clinicaltrials.gov/study/NCT03971409) | Laura Huppert, MD, B | Patient has HER2 positive, ER positive, PR negative breast cancer, but trial is specifically for triple negative breast cancer. |
| [NCT04568616](https://clinicaltrials.gov/study/NCT04568616) | Dartmouth-Hitchcock  | Patient has HER2 positive breast cancer, trial requires HER2 negative. |
| [NCT04862663](https://clinicaltrials.gov/study/NCT04862663) | AstraZeneca | Trial is for HR+/HER2- breast cancer, but patient has HER2-positive breast cancer. |
| [NCT04802759](https://clinicaltrials.gov/study/NCT04802759) | Hoffmann-La Roche | Patient has HER2-positive breast cancer, which conflicts with inclusion criteria for Cohort 1 that excludes known HER2-positive disease |
| [NCT05455619](https://clinicaltrials.gov/study/NCT05455619) | SynDevRx, Inc. | Patient has HER2-positive cancer whereas the trial targets HR+/HER2-negative breast cancer. |
| [NCT05696626](https://clinicaltrials.gov/study/NCT05696626) | Sermonix Pharmaceuti | Patient has HER2 positive breast cancer while the trial is focused on ER+/HER2- breast cancer. |
| [NCT06028022](https://clinicaltrials.gov/study/NCT06028022) | Mayo Clinic | Patient is premenopausal, while the trial requires postmenopausal patients. |
| [NCT05894239](https://clinicaltrials.gov/study/NCT05894239) | Hoffmann-La Roche | Trial requires treatment-naive patients, patient has received multiple prior therapies including TCHP, trastuzumab, pertuzumab, docetaxel, and T-DM1 |
| [NCT06062498](https://clinicaltrials.gov/study/NCT06062498) | Northwestern Univers | Patient has HER2 positive breast cancer, but trial requires ER-positive and HER2-negative cancer as per inclusion criteria. |
| [NCT06099769](https://clinicaltrials.gov/study/NCT06099769) | Memorial Sloan Kette | Patient has HER2-positive breast cancer, while trial specifically requires AR+ breast cancer with TNBC or ER-low classification. |
| [NCT06439693](https://clinicaltrials.gov/study/NCT06439693) | Dana-Farber Cancer I | Patient has prior systemic therapy for invasive breast cancer (TCHP, trastuzumab, pertuzumab, docetaxel, T-DM1) while trial requires no prior systemic therapy except first-line THP. |
| [NCT06678269](https://clinicaltrials.gov/study/NCT06678269) | Memorial Sloan Kette | Patient has HER2 positive cancer, while the trial is for HER2-negative breast cancer |
| [NCT05985655](https://clinicaltrials.gov/study/NCT05985655) | Exscientia AI Ltd.,  | The trial is for HR+ HER2- breast carcinoma, while the patient is HR+ HER2 positive. |
| [NCT04563507](https://clinicaltrials.gov/study/NCT04563507) | Weill Medical Colleg | Patient has HER2 positive status, whereas trial is for HR+ HER2- metastatic breast cancer. |
| [NCT06401889](https://clinicaltrials.gov/study/NCT06401889) | Mayo Clinic | Patient is currently undergoing second-line T-DM1 therapy, which conflicts with the inclusion criteria requiring no prior chemotherapy or endocrine therapy for current breast cancer. |
| [NCT04886531](https://clinicaltrials.gov/study/NCT04886531) | Ruth O'Regan | Patient is premenopausal and trial requires postmenopausal females |
| [NCT06590857](https://clinicaltrials.gov/study/NCT06590857) | RayzeBio, Inc. | Patient has HER2-positive breast cancer, while trial is for HER2-negative breast cancer. |
| [NCT06525766](https://clinicaltrials.gov/study/NCT06525766) | Mayo Clinic | Patient has HER2-positive breast cancer, but the trial is for ER positive, HER2-negative patients. |
| [NCT04553770](https://clinicaltrials.gov/study/NCT04553770) | Jonsson Comprehensiv | Patient has recurrent/metastatic breast cancer; trial only includes previously untreated operable invasive carcinoma of the breast. |
| [NCT04573231](https://clinicaltrials.gov/study/NCT04573231) | University of Wiscon | Patient has HER2-positive metastatic breast cancer while trial studies HER2-negative breast cancer. |
| ... | ... | *and 29 more* |

## Search Terms Used

| Term | Source | Confidence |
|------|--------|------------|
| HER2 positive | manual | 1.0 |
| HER2positive | manual | 0.9 |
| HER2-positive | manual | 0.9 |
| ER positive | manual | 1.0 |
| ERpositive | manual | 0.9 |
| ER-positive | manual | 0.9 |
| PR negative | manual | 1.0 |
| PRnegative | manual | 0.9 |
| PR-negative | manual | 0.9 |
| breast cancer | manual | 1.0 |
| HER2 positive breast cancer | manual | 1.0 |
| ER positive breast cancer | manual | 1.0 |
| PR negative breast cancer | manual | 1.0 |
| BC | llm | 0.8 |

## Information That Would Improve Matches

The following patient data was not provided but would help refine eligibility assessment:

- **Organ function labs** (hematology, liver, renal) - required by all interventional trials
- **Measurable disease status** (per RECIST 1.1) - required for most therapeutic trials
- **Life expectancy estimate** - many trials require â‰¥3 months
